The startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other drugmakers.

Recent findings provide one of the most detailed pictures to date of the genetic architecture of schizophrenia, opening up new avenues for research into the disorder.

Early-life stress increased SETD7 and H3K4me1 in the ventral tegmental area of mice, creating an epigenetically primed state that heightened later transcriptional, neuronal, and behavioral responses ...